Autor: |
Fakih, Misbah, Basheer, Faisal, Khan, Qamar uz Zaman, Hashmi, Fasih, Asad, Hafsa |
Předmět: |
|
Zdroj: |
Pakistan Armed Forces Medical Journal; Oct2022, Vol. 72 Issue 5, p1743-1743, 1p |
Abstrakt: |
ABSTRACT Objective: To assess the immunogenicity of the Hepatitis B Vaccine in children with thalassemia. Study Design: Prospective longitudinal study. Place and Duration of Study: Pak Emirates Military Hospital, Rawalpindi Pakistan from Aug 2018 to Jan 2019. Methodology: After ethical approval and informed consent, 150 diagnosed patients with thalassemia were selected from the Thalassemia centre at Pak Emirates Military Hospital Rawalpindi. The patients' transfusion, vaccination history and clinical data were obtained. The patient's sera were tested for AntiHepatitis B surface antibodies (antiHBs) by ELISA. The patients who showed seroprotection (antiHBs titer>10 IU/L) were taken as a case group. Results: Out of 150 patients, only 22% (33 patients) showed seroprotection (antiHbs titer >10 IU/L). Children younger than four years had significantly positive antiHBs (p-value=0.067) at a 5% significance level. Time since the last vaccination was also a significant factor, with the 3.76±3.072 years range exhibiting better protection (p=0.002). Conclusion: Protective AntiHBs titer was reduced after the age of 4 years in our patients, so we recommend screening patients with thalassemia after four years to assess the need for a booster dose. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|